Soligenix, Inc. (LON:0A6I)

Market Cap	9.23M
Revenue (ttm)	n/a
Net Income (ttm)	-7.56M
Shares Out	n/a
EPS (ttm)	-2.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,445
Average Volume	50,171
Open	2.955
Previous Close	2.970
Day's Range	2.890 - 2.985
52-Week Range	1.105 - 6.200
Beta	n/a
RSI	49.83
Earnings Date	Nov 10, 2025

About Soligenix

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflam...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 16
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A6I

Financial Performance

In 2024, Soligenix's revenue was $119,371, a decrease of -85.78% compared to the previous year's $839,359. Losses were -$8.27 million, 34.6% more than in 2023.

Financial numbers in USD